Schering Rebetron Hepatitis C Therapy Five Year Phase IV Data Requested

Schering-Plough will submit five-year follow-up data from its four pivotal trials of Rebetron as part of its Phase IV commitments to FDA. The combination therapy of Schering's Intron A (interferon alfa-2b) injection and Rebetol (Schering/ICN's ribavirin) for hepatitis C was approved June 3.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet